News Release

<< Back
Codexis Reports Second Quarter 2012 Results

-- Conference call today at 4:30 pm ET --

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 9, 2012-- Codexis, Inc. (NASDAQ: CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceuticals, today announced financial results for the second quarter ended June 30, 2012.

“The remainder of 2012 is an important transition period for Codexis,” said John Nicols, President and CEO of Codexis. “We are driving Codexis into a new phase of commercial execution, imparting an efficient, profit-driven culture throughout the organization. We are deploying our unique technology platform to advance our position in pharmaceuticals and to deliver against significant opportunities in fuels and chemicals.”

Second Quarter Financial Highlights:

Revenue and Gross Profit: For the second quarter of 2012, the company reported revenues of $22.9 million, a 12% decrease from $26.1 million in the second quarter of 2011. Product revenue in the second quarter of 2012 was $6.8 million, a 19% decrease from $8.4 million in the prior year quarter, due to the timing of pharmaceutical product orders. Product gross profit in the second quarter was $1.0 million, down from $1.3 million in the prior year quarter primarily due to lower product sales. Product gross margin in the second quarter was 14%, compared to 15% in the prior year quarter due to a higher percentage of generic products sales in the second quarter of 2012. Collaborative research and development revenue of $15.9 million decreased 9% from $17.4 million in the second quarter of 2011, a result of R&D funding reductions in our fuels and carbon capture programs that were taken in the second half of 2011.

Operating Expenses: Research and development expenses in the second quarter of 2012 were $15.7 million, an increase of 5% from $15.0 million for the second quarter of 2011. The increase was primarily due to headcount additions made in the second half of 2011 for the development of CodeXol™ Detergent Alcohol. Selling, general and administrative expenses in the second quarter of 2012 were $6.8 million, a decrease of 27% compared to $9.3 million in the same period of 2011. The decrease was primarily due to reductions in headcount and other discretionary expenses during the second quarter of 2012. Sequential reductions in total operating expenses of 13% for the second quarter of 2012 compared to the first quarter helped to improve our sequential quarterly net income result by $3.3 million.

Net Loss: Net loss was ($5.5) million, or ($0.15) per share, based on 36.3 million weighted average common shares outstanding in the second quarter of 2012. This compares to a net loss of ($5.0) million or ($0.14) per share during the second quarter of 2011.

Adjusted EBITDA: On a non-GAAP basis, Adjusted EBITDA was ($0.4) million in the second quarter of 2012 compared to $0.1 million for the second quarter of 2011. Adjusted EBITDA is calculated by adjusting net loss for net interest expense, income taxes, depreciation, amortization, and stock-based compensation. A reconciliation of net loss to Adjusted EBITDA is presented below.

Cash: Cash, cash equivalents, and marketable securities at June 30, 2012 were $57.4 million, a $4.7 million decrease compared to $62.2 million at March 31, 2012. The company used $3.9 million in cash from operations in the second quarter of 2012.


Codexis' statements with regard to its outlook are based on current expectations. The following statements are forward looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below.

Codexis is adjusting its revenue forecast for the full year 2012 and now expects a decline in total revenues relative to its full year 2011 total revenues of $124 million. The company also now expects 2012 Adjusted EBITDA to be negative and anticipates its year-end cash, cash equivalents, and marketable securities, excluding any special items, to be approximately $50 million.

“Given the recently announced Exclusive Negotiation Agreement we entered into with Shell, we are expecting and are planning for Shell to deliver notice of a reduction in funding under our collaborative agreement by 48 FTEs effective September 1,” said Mr. Nicols. “In addition, although we have not received any formal notice from Shell, we do not currently expect any continued Shell FTE funding after October 31. In pharmaceutical products, we are revising our forecast to account for a shift in timing of orders for certain on-patent products. As a result, we now forecast total product sales in line with last year’s result of $49 million.

“Despite these near term challenges, Codexis remains encouraged and enthusiastic about monetizing its technology going forward. For example, for second generation ethanol, we continue to make progress developing our competitively advantaged enzyme package, as well as securing the right to market these enzymes to other fuel companies outside of Shell,” Nicols added.

Conference Call

Codexis will hold a conference call on Thursday, August 9, 2012, at 4:30 p.m. Eastern Time. The conference call dial-in numbers are US: 866-788-0541 or International: 857-350-1679, access code 54501345. A live webcast of the call will also be available from the Investors section of A recording of the call will be available by calling US: 888-286-8010 or International: 617-801-6888, access code 23138971 beginning approximately two hours after the call, and will be available for up to seven days. A webcast replay will also be available from the Investors section of approximately two hours after the call, and will be available for up to 30 days.

About Codexis, Inc.

Codexis, Inc. is a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceuticals. Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis’ forecast for 2012 revenue, Adjusted EBITDA, total cash burn and total pharmaceutical product sales; Codexis’ ability to advance its position in pharmaceuticals and to deliver against opportunities in fuels and chemicals; Codexis’ ability to monetize its technology; Codexis’ ability to develop its enzyme package for second generation ethanol; Codexis’ ability to obtain the right to market its enzymes in the biofuels field to parties other than Shell; and Codexis’ expectation that Shell will notify it of a reduction in funding of FTEs under Codexis’ collaboration with Shell effective September 1, 2012 and discontinue FTE funding after October 31, 2012. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include Codexis’ need for substantial additional capital in the future in order to expand its business, Codexis’ dependence on its collaborators, Codexis’ heavy dependence on its collaborative research agreement with Shell and the risks that Shell may provide notice of a reduction in funding of FTEs under that agreement and that Codexis’ collaboration with Shell may not be extended beyond October 31, 2012; Codexis’ dependence on a limited number of products and customers in its pharmaceutical business; various challenges to the feasibility of the production and commercialization of biofuels and bio-based chemicals derived from cellulose and Codexis’ limited experience manufacturing and selling cellulase enzymes; and the risk that Codexis may not be able to obtain from Shell the right to market Codexis’ enzymes in the biofuels field to parties other than Shell. Additional factors that could materially affect actual results can be found in Codexis’ Quarterly Report on Form 10-Q for the period ended June 30, 2012 filed with the Securities and Exchange Commission on August 9, 2012, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Codexis, Inc.
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
  Three Months Ending     Six Months Ending  
June 30, June 30,
  2012       2011   % change   2012       2011   % change
Product $ 6,783 $ 8,397 -19 % $ 21,949 $ 21,329 3 %
Collaborative research and development 15,868 17,385 -9 % 30,480 34,871 -13 %
Government awards   258     273   -5 %   1,616     889   82 %
Total revenues   22,909     26,055   -12 %   54,045     57,089   -5 %
Costs and operating expenses:
Cost of product revenues 5,829 7,106 -18 % 18,471 18,756 -2 %
Gross margin $ 954 1,291 -26 % 3,478 2,573 35 %
Gross margin % 14 % 15 % 16 % 12 %
Research and development 15,650 14,965 5 % 31,999 28,715 11 %
Selling, general and administrative   6,789     9,276   -27 %   16,184     18,289   -12 %
Total costs and operating expenses   28,268     31,347   -10 %   66,654     65,760   1 %
Loss from operations (5,359 ) (5,292 ) 1 % (12,609 ) (8,671 ) 45 %
Interest income 74 71 4 % 149 120 24 %
Interest expense and other, net   (157 )   16   nm   (275 )   34   nm
Loss before provision (benefit) for income taxes (5,442 ) (5,205 ) 5 % (12,735 ) (8,517 ) 50 %
Provision (benefit) for income taxes   77     (165 ) nm   274     (6 ) nm
Net loss $ (5,519 ) $ (5,040 ) 10 % $ (13,009 ) $ (8,511 ) 53 %
Net loss per share of common stock,
basic and diluted $ (0.15 ) $ (0.14 ) $ (0.36 ) $ (0.24 )
Weighted average common shares used in computing net loss per share of common stock, basic and diluted   36,296     35,685     36,177     35,402  
Codexis, Inc.
Condensed Consolidated Balance Sheets
(In Thousands)
  June 30,     December 31,
  2012     2011  
Current assets:
Cash and cash equivalents $ 16,693 $ 25,762
Marketable securities 34,671 27,720
Accounts receivable, net 8,124 18,917
Inventories 4,201 4,488
Prepaid expenses and other current assets   5,144     2,345  
Total current assets 68,833 79,232
Restricted cash 1,511 1,511
Non-current marketable securities 6,062 10,348
Property and equipment, net 22,073 24,176
Intangible assets, net 14,636 16,442
Goodwill 3,241 3,241
Other non-current assets   1,316     972  
Total assets $ 117,672   $ 135,922  
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 4,313 $ 10,364
Accrued compensation 4,189 6,785
Other accrued liabilities 7,496 7,354
Deferred revenues   3,647     3,789  
Total current liabilities 19,645 28,292
Deferred revenues, net of current portion 1,393 1,485
Other long-term liabilities   4,126     3,455  
Total liabilities 25,164 33,232
Stockholders' equity:
Common stock 4 4
Additional paid-in capital 291,090 287,792
Accumulated other comprehensive loss (878 ) (407 )
Accumulated deficit   (197,708 )   (184,699 )
Total stockholders' equity   92,508     102,690  
Total liabilities and stockholders' equity $ 117,672   $ 135,922  
Codexis, Inc.
Condensed Consolidated Statements of Cash Flow
(In Thousands)
  Six Months Ending
June 30,
  2012       2011  
Operating activities:
Net loss $ (13,009 ) $ (8,511 )
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible assets 1,806 1,858
Depreciation and amortization of property and equipment 4,544 3,760
Loss on disposal of property and equipment 109 59
Gain from extinguishment of asset retirement obligation - (124 )
Stock-based compensation 3,077 4,856
Accretion of asset retirement obligation 15 29
Amortization of premium on marketable securities 377 51
Changes in operating assets and liabilities:
Accounts receivable 10,793 4,027
Inventories 287 (1,370 )
Prepaid expenses and other current assets (2,799 ) (735 )
Other assets (409 ) (13 )
Accounts payable (6,051 ) (1,493 )
Accrued compensation (2,596 ) (3,088 )
Other accrued liabilities 798 2,554
Deferred revenues   (234 )   (2,203 )
Net cash used in operating activities   (3,292 )   (343 )
Investing activities:
Increase in restricted cash - (46 )
Purchase of property and equipment (2,551 ) (4,187 )
Purchase of marketable securities (19,141 ) (38,152 )
Proceeds from sale of marketable securities 10,500 -
Proceeds from maturities of marketable securities   4,964     -  
Net cash used in investing activities   (6,228 )   (42,385 )
Financing activities:
Proceeds from exercises of stock options   287     2,390  
Net cash provided by financing activities   287     2,390  
Effect of exchange rate changes on cash and cash equivalents   164     24  
Net increase in cash and cash equivalents (9,069 ) (40,314 )
Cash and cash equivalents:
Beginning of the period   25,762     72,396  
End of the period 16,693 32,082
Marketable securities at the end of period 40,733 40,362
Cash, cash equivalents and marketable securities $ 57,426   $ 72,444  

Reconciliation of GAAP to Non-GAAP Financial Information

In this press release, in addition to GAAP financial results, we present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA to evaluate the effectiveness of our business strategies.

A reconciliation of GAAP net loss to Adjusted EBITDA is included in the table below.


Codexis, Inc.

Reconciliation of GAAP Net Loss to Adjusted EBITDA

(In Thousands)
  Three Months Ending   Six Months Ending
June 30, June 30,

Calculation of Adjusted EBITDA

  2012       2011     2012       2011  
Net loss $ (5,519 ) $ (5,040 ) $ (13,009 ) $ (8,511 )
Minus: Interest income (74 ) (71 ) (149 ) (120 )
Plus: Income taxes 77 (165 ) 274 (6 )
Plus: Depreciation and amortization 3,231 2,794 6,350 5,618
Plus: Stock-based compensation 1,908 2,549 3,077 4,835
Adjusted EBITDA $ (377 ) $ 67   $ (3,457 ) $ 1,816  

Adjusted EBITDA has limitations as an analytical tool. Some of these limitations are:

  • Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
  • Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
  • Non-cash compensation is and will remain a key element of our overall long-term incentive compensation package, although we exclude it as an expense when evaluating our ongoing operating performance for a particular period.

Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally.

Source: Codexis, Inc.

Codexis, Inc.
Investors: 212-362-1200
Kelly McAlearney, 415-503-4073

Print Page Print Page | E-mail Page E-mail Page |

Share Page

| Financial Tear Sheet Tear Sheet


We are an industrial biotechnology company providing unique, state-of-the-art enzyme optmization services and biocatalyst products.


Codexis offers complete biocatalysis solutions from “off-the-shelf” enzymes and Screening Kits, to commercial supply of biocatalysts.



Our protein engineering technology enables the rapid development of custom-designed enzymes



Visit our Media Center for the latest press information, videos, imagery, and technical papers.


Continued success at Codexis depends on the innovation, collaboration and commitment of people who are passionate about what they do



Access to Codexis information for the investment community

You are now leaving this website. If you would like to continue, click Continue.